1 / 20

Dr. Jean-Herv é Bradol

Dr. Jean-Herv é Bradol Research Director MSF Center for Reflection on Humanitarian Action & Knowledge. Medical Innovation in Humanitarian Situations: The Work of Médecins Sans Frontières. MSF Malaria Studies 1996-2004.

sulwyn
Download Presentation

Dr. Jean-Herv é Bradol

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dr. Jean-Hervé Bradol Research DirectorMSF Center for Reflection on Humanitarian Action & Knowledge Medical Innovation in Humanitarian Situations: The Work of Médecins Sans Frontières

  2. MSF Malaria Studies 1996-2004 • More than 12,000 patients were enrolled in 43 efficacy studies in 18 countries of Asia and Africa between 1996 and 2004. • This accounted for 1/4 of the overall research output in these countries during that period. • The vast majority of the studies were published in peer-reviewed journals Guthmann J.-P., Checchi F. et al., 2008, « Assessing Antimalarial Efficacy in a time of Change to Artemisinine-Based Combination Therapies : The Role of Médecins Sans Frontières », Plos Medicine, 5 (8), p. 1191-1199.

  3. Requirements to be met: • The treatment must be accepted by the WHO • Reliable supply sources must be identified – they must be sustainable, of good quality and reasonably priced • Economic conditions must be created to finance the new protocol • Legal questions must be addressed (intellectual property) • Administrative authorisations from national authorities must be obtained on import and use • New treatment protocols must be written and staff trained

  4. Cholera: diagnosis and treatment outside the hospital Jean François Corty Meningitis: from practitioner to prescriber Eugénie d’Alessandro Human African trypanosomiasis: moving beyond arsenic Jean François Corty Malaria: resistances treated by south-south mediation Suna Balkan and Jean-François Corty AIDS: a new pandemic requiring new medical and political practices Jean-Hervé Bradol and Elizabeth Szumilin Medical Innovation in Humanitarian SituationsThe Work of Médecins Sans FrontièresEdited by Jean-Hervé Bradol and Claudine Vidal • Innovations? • Jean-Hervé Bradol and Marc Le Pape • MSF “satellites”. A strategy underlying different medical practices • Claudine Vidal and Jacques Pinel • Measure, analyse, publish and innovate • Emmanuel Baron • Controversy policy • Marc Le Pape and Isabelle Defourny • Remarks • Nicolas Dodier

  5. New drugs developed from 1975-2004 Total: 1,556 Tropical diseases: 18 1.3% TB: 3 Tropical diseases and tuberculosis account for 12% of the global disease burden, but only 1.3% of new drugs developed. Source: Chirac P, Torreele E. Lancet. 2006 May 12; 1560-1561.

  6. Organizations Activities 2000: A Deserted R&D Landscape Specific TDR Unspecified CHALLENGE 4 GSK CHALLENGE 4 Launch & utilization Launch & utilization CHALLENGE 3 WRAIR CHALLENGE 3 Registration Phase 3 Phase 2 Phase 1 CHALLENGE 2 Regulatory toxicity & safety In vivo efficacy Lead optimization CHALLENGE 1 Lead identification Screening Visceral Leishmaniasis Cutaneous Leishmaniasis Chagas HAT

  7. 2007 Drug R&D Landscape for NTDs Organizations Activities Specific TDR CDND Unspecified TB Alliance NITD – PC dengue, TB IOWH CHALLENGE 4 MMV Launch & utilization GSK DNDi DD@D CHALLENGE 3 Sandler Center WRAIR Registration Phase 3 Phase 2 Phase 1 TB HAT Chagas Dengue Malaria Visceral Leishmaniasis Cutaneous Leishmaniasis CHALLENGE 2 Regulatory toxicity & safety In vivo efficacy Lead optimization CHALLENGE 1 Lead identification Screening

  8. 8 Combined PDP pipeline today includes 143 candidates 104 biopharmaceutical candidates in development... ... and 39 diagnostic & vector control candidates Diagnostics Pre Clinical 59 57% Feasibility 7 26% • Test • Development Phase I 15 14% 7 26% Evaluation 6 22% Phase II 12 12% CD4 Demonstration 1 4% FIND Phase III 10 10% • Country • Adoption IDRI 6 22% Drugs Registration 2 2% Vaccines Vector control Microbicides Launched 6 6% Early Stage IVCC • In • Development # candidates # candidates Notes: Includes products not funded by Gates Foundation. Biopharmaceutical candidates in development Include: IAVI, IPM, IVI, GATB, Aeras, MMV, MVI, MVP, PVS, DNDi, iOWH, PDVI, HHVI. Source: PDPs

  9. Product Development Partnerships (PDPs): Filling the Gaps in Translational Research and Product Development

More Related